home / stock / cprx / cprx news

CPRX News and Press, Catalyst Pharmaceuticals Inc. From 11/08/23

Stock Information
Company Name: Catalyst Pharmaceuticals Inc.
Stock Symbol: CPRX
Market: NASDAQ
Website: catalystpharma.com
Menu
CPRX CPRX Quote CPRX Short CPRX News CPRX Articles CPRX Message Board
Get CPRX Alerts

News, Short Squeeze, Breakout and More Instantly...
CPRX - Expected earnings - Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc. (CPRX) is expected to report $-0.24 for Q3 2023
CPRX - Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®

CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, to...

CPRX - Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity

2023-10-31 16:13:22 ET Summary Staring Catalyst Pharmaceuticals, Inc. coverage with a Buy rating with a 2-5-year target of $40 based on discounted cash flow valuation, offering 3x upside potential. The company has two FDA-approved products, Firdapse and Fycompa, with 92% annual re...

CPRX - Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo

CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today a...
CPRX - FDA approves Catalyst, Santhera drug Agamree for Duchenne MD

2023-10-26 16:34:53 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals: The Journey From Earnings Euphoria To Patent Perils Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2023 Earnings Call Transcript Catalyst gets FDA review for higher dose of Firdapse for rare ...

CPRX - Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

AGAMREE ® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for Duchenne Muscular Dystrophy and Other Potential Indications Novel Cor...

CPRX - Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023

CORAL GABLES, Fla., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that...
CPRX - Catalyst Pharmaceuticals appoints Richard Daly as its new CEO

2023-10-19 08:43:04 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals: The Journey From Earnings Euphoria To Patent Perils Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2023 Earnings Call Transcript For further details see: Catalyst Pharmaceuticals appoints...

CPRX - Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer

CORAL GABLES, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today a...

CPRX - Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida

CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that Patrick J. McEnany, Founder, Chairman and CEO of Catalyst, has been bestowed the 202...
Previous 10 Next 10